Update of a prognostic survival model in head and neck squamous cell carcinoma patients treated with immune checkpoint inhibitors using an expansion cohort

BACKGROUND: Immune checkpoint inhibitors (ICI) treatment in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) offers new therapeutic venues. We have previously developed a predictive survival model in this patient population based on clinical parameters, and the purpose of thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Issa, Majd, Klamer, Brett G., Mladkova, Nikol, Laliotis, Georgios I., Karivedu, Vidhya, Bhateja, Priyanka, Byington, Chase, Dibs, Khaled, Pan, Xueliang, Chakravarti, Arnab, Grecula, John, Jhawar, Sachin R., Mitchell, Darrion, Baliga, Sujith, Old, Matthew, Carrau, Ricardo L., Rocco, James W., Blakaj, Dukagjin M., Bonomi, Marcelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284772/
https://www.ncbi.nlm.nih.gov/pubmed/35836204
http://dx.doi.org/10.1186/s12885-022-09809-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284772/
https://www.ncbi.nlm.nih.gov/pubmed/35836204
http://dx.doi.org/10.1186/s12885-022-09809-5

Ejemplares similares